GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - PYXIS ONCOLOGY INC

Explicit Guidance:

• Regulatory & Clinical Milestones:
  • Expected disclosure of full 2027 regulatory plan in "early 2027" to support expedited delivery of MiCMO to patients.
  • End of Phase 2 meeting update regarding "Project Optimist" and dose selection scheduled for the first quarter of 2027.
  • Confirmation of dose selection: Management expects to move forward with 5.4 mg/kg with a dose cap based on September data, pending agency discussion in Q1 2027.
  • Frontline Combination Data (with pembrolizumab): Expected updated data set (20 patients, multiple doses) to be disclosed in December 2026 focusing on dose-response and safety.
  • Frontline Durability Data: Updated data evaluating durability (Overall Survival) for the combination therapy expected in the second half of 2027.
• Timeline Milestones:
  • First Patient Dosed (FPD) in the pivotal "Headliner" trial (Phase 3) targeted for the middle part of 2027.
  • Data presentation at the Triple Meeting (ESMO) in Barcelona scheduled for "a couple of weeks" from the call date.

Business-Segment Outlook:

• Head & Neck Cancer (Core Focus):
  • Target Indication: Second-line treatment is the primary near-term market; current data supports universal efficacy regardless of prior standard-of-care (platinum/PD-1 or EGFR bispecifics).
  • Market Size: Identified opportunity of >20,000 patients annually in the US seeking second-line treatment, with ~70% of frontline patients progressing to this line.
  • Biomarker Strategy: Drug is positioned as biomarker-agnostic; efficacy observed regardless of HPV status or EDBFN-H score, though further investigation into potential sub-population benefit continues.
  • Strategic Shift: Decision made to prioritize the second-line opportunity to maximize impact and resource efficiency, avoiding dilution of focus despite broad activity in other tumor types.
• Frontline Expansion:
  • Combination therapy with pembrolizumab in the first-line setting is under investigation; decision on proceeding to further development (likely Phase 2/3) contingent on December 2026 and H2 2027 data readouts.
• Pipeline Diversification:
  • Basket Study Results: Activity observed in 9 tumor types including breast, lung, pancreatic cancer, and sarcoma.
  • Investment Strategy: Future asset prioritization will strictly follow a "two-criteria" filter: demonstrated clinical activity in clinic AND potential to become standard of care in a large enough population.

Market and Competitive Outlook:

• Competitive Landscape: Acknowledges a changing frontline standard of care (e.g., amivantamab approvals) which will subsequently create a larger unmet need in the second-line setting where options are currently limited.
• Product Positioning: MiCMO positioned to address the "void" left when frontline therapies advance, offering a broad efficacy profile for patients who have failed current standard-of-care regimens.
• Pricing/Reimbursement: No explicit guidance provided; however, management highlights the critical nature of the unmet need to justify market entry.

Macro / Industry Outlook:

• Regulatory Environment:
  • Active collaboration with FDA and EMA concluded at the end of 2025.
  • Trial design ("Headliner") optimized for global standard-of-care comparators (cetuximab, docetaxel, methotrexate) to facilitate worldwide adoption.
• Industry Trends: Observes increasing investment in head and neck cancer and validation of ADC efficacy across solid tumors via the extracellular matrix targeting mechanism.

Strategic Initiatives:

• Clinical Execution:
  • Immediate priority: Enroll the "Headliner" trial (Phase 3) as quickly as possible with an aim for FPD in mid-2027.
  • Investigator Engagement: Hosting a data presentation at the Triple Meeting in Barcelona to build consensus and enthusiasm.
• Partnership Strategy:
  • Current Stance: Company retains 100% rights and is fully focused on standalone execution of the pivotal trial.
  • Future Outlook: Willing to engage in discussions with potential partners to "pressure test" strategy, but no immediate intent to divest or partner for the current program.
• Operational Adjustments: Implementation of modified weight-based dosing (dose cap) to mitigate peripheral neuropathy risks, successfully reducing discontinuation and Grade 3 neuropathy rates by nearly half.

Risks and Headwinds to Outlook:

• Clinical Safety: Persistent focus on peripheral neuropathy; while data suggests it occurs late and resolves after dose holidays, it remains a key safety signal that could impact tolerability if not managed.
• Development Timeline: Progression to Phase 3 and subsequent data readouts (H2 2027) is contingent on the successful enrollment and execution of current studies.
• Resource Allocation: Management notes the need to be "judicious with resources," implying that expansion into other tumor types beyond head and neck is dependent on strong clinical signals and financial capacity.
• Competitive Velocity: Rapid evolution of the frontline standard of care (e.g., emerging data on EGFR bispecifics) could alter the patient population dynamics before MiCMO launches.

Management Tone on the Future:

• Confidence Level: High confidence in the clinical signal ("very clear," "universal efficacy") and the strategic decision to focus on the second-line indication.
• Urgency: Strong emphasis on speed ("first patient dosed as quickly as possible," "deliver this drug... as quickly as possible") driven by the significant unmet need.
• Cautious Optimism: While data is encouraging, management uses "hedges" regarding future decisions (e.g., "decide if it is worthy of additional investigation" for frontline) pending final data readouts.
• Transparency: Proactive communication of timeline adjustments (e.g., delaying dose confirmation discussion to Q1 2027 to align with agency feedback).